{
  "nctrialId": "HC-1769",
  "title": "A Randomized Double-Blind, Placebo-Controlled  Study of CDN-468 (integrin inhibitor) in Patients With Multiple Sclerosis",
  "officialTitle": "A Randomized Double-Blind, Placebo-Controlled  Study of CDN-468 (integrin inhibitor) in Patients With Multiple Sclerosis",
  "sponsor": "University of British Columbia",
  "indication": "Multiple Sclerosis",
  "phase": "Phase 2/Phase 3",
  "fileName": "HC-1769.json",
  "fileSize": 230881,
  "date": "2024-10-28",
  "completionDate": "2026-09-09",
  "drugName": "CDN-468 (integrin inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Active, not recruiting",
  "description": "This is a randomized double-blind, placebo-controlled  study designed to evaluate the efficacy and safety of CDN-468 (integrin inhibitor) in patients with Multiple Sclerosis. The study will enroll approximately 240 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 26-83 years\n- Confirmed diagnosis of Multiple Sclerosis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}